Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sharon Tentarelli

Showing results (11-20 of 19) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 19 results.
Nature Chemical Biology|September 6, 2016
Inhibition of Mcl-1 through covalent modification of a noncatalytic lysine side chainGizem Akçay, Matthew A Belmonte, Brian Aquila, et al.
Chembiochem : a European Journal of Chemical Biology|August 4, 2015
Discovery and Characterization of New Hydroxamate Siderophores, Baumannoferrin A and B, produced by Acinetobacter baumanniiWilliam F Penwell, Nancy DeGrace, Sharon Tentarelli, et al.
Journal of Medicinal Chemistry|November 14, 2024
Design and Synthesis of Acyclic Boronic Acid Arginase InhibitorsJason D Shields, Brian M Aquila, David Emmons, et al.
Journal of Medicinal Chemistry|April 26, 2021
Fragment-Based Design of a Potent MAT2a Inhibitor and <i>in Vivo</i> Evaluation in an MTAP Null Xenograft ModelClaudia De Fusco, Marianne Schimpl, Ulf Börjesson, et al.
Journal of Medicinal Chemistry|November 22, 2024
Discovery of (2<i>R</i>,4<i>R</i>)-4-((<i>S</i>)-2-Amino-3-methylbutanamido)-2-(4-boronobutyl)pyrrolidine-2-carboxylic Acid (AZD0011), an Actively Transported Prodrug of a Potent Arginase Inhibitor to Treat CancerScott N Mlynarski, Brian M Aquila, Susan Cantin, et al.
Journal of Medicinal Chemistry|September 28, 2024
Optimization of Potent, Efficacious, Selective and Blood-Brain Barrier Penetrating Inhibitors Targeting EGFR Exon20 Insertion MutationsClare Thomson, Erin Braybrooke, Nicola Colclough, et al.
Molecular Cancer Therapeutics|March 13, 2023
Novel Arginase Inhibitor, AZD0011, Demonstrates Immune Cell Stimulation and Antitumor Efficacy with Diverse Combination PartnersAatman S Doshi, Susan Cantin, Marylens Hernandez, et al.
Journal of Medicinal Chemistry|March 11, 2024
Development of a Series of Pyrrolopyridone MAT2A InhibitorsStephen J Atkinson, Sharan K Bagal, Argyrides Argyrou, et al.
Journal of Medicinal Chemistry|September 3, 2021
Optimization of an Imidazo[1,2-<i>a</i>]pyridine Series to Afford Highly Selective Type I1/2 Dual Mer/Axl Kinase Inhibitors with <i>In Vivo</i> EfficacyWilliam McCoull, Scott Boyd, Martin R Brown, et al.
Pageof 2

Showing results (11-20 of 19) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
Nature Chemical Biology|September 6, 2016
Inhibition of Mcl-1 through covalent modification of a noncatalytic lysine side chainGizem Akçay, Matthew A Belmonte, Brian Aquila, et al.
Chembiochem : a European Journal of Chemical Biology|August 4, 2015
Discovery and Characterization of New Hydroxamate Siderophores, Baumannoferrin A and B, produced by Acinetobacter baumanniiWilliam F Penwell, Nancy DeGrace, Sharon Tentarelli, et al.
Journal of Medicinal Chemistry|November 14, 2024
Design and Synthesis of Acyclic Boronic Acid Arginase InhibitorsJason D Shields, Brian M Aquila, David Emmons, et al.
Journal of Medicinal Chemistry|April 26, 2021
Fragment-Based Design of a Potent MAT2a Inhibitor and <i>in Vivo</i> Evaluation in an MTAP Null Xenograft ModelClaudia De Fusco, Marianne Schimpl, Ulf Börjesson, et al.
Journal of Medicinal Chemistry|November 22, 2024
Discovery of (2<i>R</i>,4<i>R</i>)-4-((<i>S</i>)-2-Amino-3-methylbutanamido)-2-(4-boronobutyl)pyrrolidine-2-carboxylic Acid (AZD0011), an Actively Transported Prodrug of a Potent Arginase Inhibitor to Treat CancerScott N Mlynarski, Brian M Aquila, Susan Cantin, et al.
Journal of Medicinal Chemistry|September 28, 2024
Optimization of Potent, Efficacious, Selective and Blood-Brain Barrier Penetrating Inhibitors Targeting EGFR Exon20 Insertion MutationsClare Thomson, Erin Braybrooke, Nicola Colclough, et al.
Molecular Cancer Therapeutics|March 13, 2023
Novel Arginase Inhibitor, AZD0011, Demonstrates Immune Cell Stimulation and Antitumor Efficacy with Diverse Combination PartnersAatman S Doshi, Susan Cantin, Marylens Hernandez, et al.
Journal of Medicinal Chemistry|March 11, 2024
Development of a Series of Pyrrolopyridone MAT2A InhibitorsStephen J Atkinson, Sharan K Bagal, Argyrides Argyrou, et al.
Journal of Medicinal Chemistry|September 3, 2021
Optimization of an Imidazo[1,2-<i>a</i>]pyridine Series to Afford Highly Selective Type I1/2 Dual Mer/Axl Kinase Inhibitors with <i>In Vivo</i> EfficacyWilliam McCoull, Scott Boyd, Martin R Brown, et al.
Pageof 2